A St. Louis startup has licensed a COVID-19 vaccine developed at Washington University that won’t be one of the first on the market, but could have advantages over other early vaccine contenders. An article in Nature this month described the Washington U. research as one of several “underdog” vaccines that could be important if early candidates fail, or confer only partial protection against COVID-19.
